Crystal structure of human DYRK1A in complex with ARN25565
Unveiling the pharmacophoric traits of balanced triple GSK-3B/FYN/DYRK1A inhibitors: rational design and synthesis of novel amino-pyrazole containing scaffolds for the treatment of Alzheimer's disease and related tauopathies.
Dual specificity tyrosine-phosphorylation-regulated kinase 1A
Dual specificity YAK1-related kinase,HP86,Protein kinase minibrain homolog,MNBH,hMNB
GPSSHKKERKVYNDGYDDDNYDYIVKNGEKWMDRYEIDSLIGKGSFGQVVKAYDRVEQEWVAIKIIKNKKAFLNQAQIEV RLLELMNKHDTEMKYYIVHLKRHFMFRNHLCLVFEMLSYNLYDLLRNTNFRGVSLNLTRKFAQQMCTALLFLATPELSII HCDLKPENILLCNPKRSAIKIVDFGSSCQLGQRIYQ(PTR)IQSRFYRSPEVLLGMPYDLAIDMWSLGCILVEMHTGEPL FSGANEVDQMNKIVEVLGIPPAHILDQAPKARKFFEKLPDGTWNLKKTKDGKREYKPPGTRKLHNILGVETGGPGGRRAG ESGHTVADYLKFKDLILRMLDYDPKTRIQPYYALQHSFFKKTADE
GPSSHKKERKVYNDGYDDDNYDYIVKNGEKWMDRYEIDSLIGKGSFGQVVKAYDRVEQEWVAIKIIKNKKAFLNQAQIEV RLLELMNKHDTEMKYYIVHLKRHFMFRNHLCLVFEMLSYNLYDLLRNTNFRGVSLNLTRKFAQQMCTALLFLATPELSII HCDLKPENILLCNPKRSAIKIVDFGSSCQLGQRIYQYIQSRFYRSPEVLLGMPYDLAIDMWSLGCILVEMHTGEPLFSGA NEVDQMNKIVEVLGIPPAHILDQAPKARKFFEKLPDGTWNLKKTKDGKREYKPPGTRKLHNILGVETGGPGGRRAGESGH TVADYLKFKDLILRMLDYDPKTRIQPYYALQHSFFKKTADE
National Institutes of Health/National Institute of General Medical Sciences (NIH/NIGMS)
kinase inhibitors, multitarget compounds, drug discovery, central nervous system, tauopathies, TRANSFERASE
SSHKKERKVYNDGYDDDNYDYIVKNGEKWMDRYEIDSLIGKGSFGQVVKAYDRVEQEWVAIKIIKNKKAFLNQAQIEVRL LELMNKHDTEMKYYIVHLKRHFMFRNHLCLVFEMLSYNLYDLLRNTNFRGVSLNLTRKFAQQMCTALLFLATPELSIIHC DLKPENILLCNPKRSAIKIVDFGSSCQLGQRIYQYIQSRFYRSPEVLLGMPYDLAIDMWSLGCILVEMHTGEPLFSGANE VDQMNKIVEVLGIPPAHILDQAPKARKFFEKLPDGTWNLKKTKDGKREYKPPGTRKLHNILGVETGGPGGRRAGESGHTV ADYLKFKDLILRMLDYDPKTRIQPYYALQHSFFKKTADE